Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp boosted its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 22.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 48,784 shares of the company’s stock after buying an additional 8,851 shares during the quarter. Bank of New York Mellon Corp owned 0.11% of Kyverna Therapeutics worth $94,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Gilead Sciences Inc. purchased a new stake in Kyverna Therapeutics during the fourth quarter valued at about $15,432,000. Geode Capital Management LLC increased its position in shares of Kyverna Therapeutics by 21.7% in the fourth quarter. Geode Capital Management LLC now owns 539,682 shares of the company’s stock worth $2,019,000 after acquiring an additional 96,370 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Kyverna Therapeutics by 2,225.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company’s stock valued at $1,728,000 after acquiring an additional 442,090 shares during the period. Integral Health Asset Management LLC lifted its position in shares of Kyverna Therapeutics by 75.0% in the 4th quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company’s stock valued at $1,309,000 after acquiring an additional 150,000 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in Kyverna Therapeutics by 16.7% in the 4th quarter. Wellington Management Group LLP now owns 274,414 shares of the company’s stock worth $1,026,000 after purchasing an additional 39,291 shares during the period. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Price Performance

NASDAQ:KYTX opened at $3.33 on Thursday. The stock has a market cap of $143.92 million, a PE ratio of -0.99 and a beta of 3.05. Kyverna Therapeutics, Inc. has a fifty-two week low of $1.78 and a fifty-two week high of $8.78. The stock’s 50-day moving average is $3.38 and its two-hundred day moving average is $2.80.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.21) by $0.18. On average, equities research analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright upgraded shares of Kyverna Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $4.00 to $5.00 in a research report on Tuesday, May 27th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $15.60.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.